Excessive pricing: the European Commission opens formal investigation into Aspen Pharma’s pricing practices for cancer medicines
On 15 May 2017 the European Commission has opened its first excessive pricing investigation in the pharmaceutical industry to assess whether Aspen Pharma has abused a dominant position by charging excessive pricing for five life-saving cancer medicines. More specifically, the investigation concerns Aspen’s pricing practices for niche medicines used for treating cancer, such as hematologic…